



SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE
STATEMENT OF ESTIMATED FISCAL IMPACT
(803)734-3780 • RFA.SC.GOV/IMPACTS

This fiscal impact statement is produced in compliance with the South Carolina Code of Laws and House and Senate rules. The focus of the analysis is on governmental expenditure and revenue impacts and may not provide a comprehensive summary of the legislation.

Bill Number: H. 4567 Prefiled on November 10, 2021
Author: Oremus
Subject: Pandemic disease and experimental treatments
Requestor: House Medical, Military, Public, and Municipal Affairs
RFA Analyst(s): Coomer
Impact Date: January 11, 2022 Updated for Additional Agency Response

Fiscal Impact Summary

This bill authorizes the use of investigational drugs or treatments for certain patients who contract an infection, illness, or other health condition caused by a declared epidemic or pandemic disease.

This bill will have no expenditure impact on the Department of Health and Environmental Control (DHEC) because it does not materially impact the duties or operations of the agency.

This bill will have no expenditure impact on the Department of Labor, Licensing and Regulation (LLR) or the Board of Medical Examiners because it does not materially impact the duties or operations of the agency or the board.

This fiscal impact statement has been updated to include a response from LLR.

Explanation of Fiscal Impact

Updated for Additional Agency Response on January 11, 2022
Prefiled on November 10, 2021

State Expenditure

This bill authorizes the use of investigational drugs or treatments for certain patients who contract an infection, illness, or other health condition caused by a declared epidemic or pandemic disease. After considering and exhausting all other treatment options currently approved by the United States Food and Drug Administration, a treating physician may give informed consent in writing to an eligible patient to use an investigational drug, biological product, or device for treatment of the declared epidemic or pandemic disease.

Department of Health and Environmental Control. This bill will have no expenditure impact on DHEC because it does not materially impact the duties or operations of the agency.

Department of Labor, Licensing and Regulation. Under the regulation of LLR, the Board of Medical Examiners is the licensing board for physicians in South Carolina. This bill will have no expenditure impact on LLR or the Board of Medical Examiners because it does not materially

impact the duties or operations of the agency or the board. *This section of the fiscal impact statement has been updated to include a response from LLR.*

State Revenue

N/A

Local Expenditure

N/A

Local Revenue

N/A

Prefiled on November 10, 2021

State Expenditure

This bill authorizes the use of investigational drugs or treatments for certain patients who contract an infection, illness, or other health condition caused by a declared epidemic or pandemic disease. After considering and exhausting all other treatment options currently approved by the United States Food and Drug Administration, a treating physician may give informed consent in writing to an eligible patient to use an investigational drug, biological product, or device for treatment of the declared epidemic or pandemic disease.

Department of Health and Environmental Control. This bill will have no expenditure impact on DHEC because it does not materially impact the duties or operations of the agency.

Department of Labor, Licensing and Regulation. Under the regulation of LLR, the Board of Medical Examiners is the licensing board for physicians in South Carolina. The expenditure impact of this bill on LLR is pending, contingent upon a response from LLR.

State Revenue

N/A

Local Expenditure

N/A

Local Revenue

N/A



Frank A. Rainwater, Executive Director